Cingulate Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cingulate Inc 's ROA in the second quarter of 2026?
Cingulate Inc recorded a cumulative net loss of $-29 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -125.68%.

However, within the Healthcare sector 781 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4415, from total ROA ranking in the first quarter of 2026 at 5143.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	167.1 %	148 %	2.08 %	-21.56 %	175.5 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-29	-28	-22	-22	-19
Return On Assets (TTM)	-125.68 %	-159.95 %	-174.35 %	-172.39 %	-139.39 %
CING's Total Ranking	# 4415	# 5143	# 4560	# 4569	# 4674
Total Assets (TTM) in million	36	31	15	11	13
Seq. Total Assets Change	16.56 %	104.74 %	43.3 %	-21.9 %	8.23 %
Seq. Net Income Change	-	-	-	-	-

CING's 5 Years Annual ROA >> Back to CING Management Effectiveness >> Compare CING ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 365
Sector	# 782
Overall	# 4312

Return On Assets Statistics
High	Average	Low
-119.8 %	-223.15 %	-448.18 %
(Dec 31 2022)		(Mar 31 2024)

News about Cingulate Inc Return on Assets ROA

Cingulate Inc. Seizes Growth Momentum: CEO Shane Schaffer Discusses ADHD Innovations Amid Financial Transformation on Big Biz Show,

In a significant development for Cingulate Inc. (NASDAQ: CING), a Kansas City-based biopharmaceutical company specialized in innovative drug delivery platforms, Shane J. Schaffer, Chairman and CEO, recently participated in the nationally syndicated Big Biz Show. During this broadcast, Schaffer provided insights into the company s leading asset, CTx-1301, which is currently undergoing Phase 3 trials for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). CTx-1301 represents the forefront of Cingulate s pipeline, which utilizes its proprietary Precision Timed Release (PTR) technology—an innovative approach designed to optimize drug absorption and efficacy. In light of the increasing prevalence of ADHD diagnoses, Cingulate s advancements in this therapeutic area could represent a meaningful contribution to the market, particularly for patients seeking more effective treatment options.While Cingulate s endeavors signal potential growth, the company has faced financial challenges as evidenced by a cumulative net loss of $24 million for the 12 months ending in the fourth quarter of 2023. This has translated to a negative return on assets (ROA) of an alarming -452.23%, positioning the company among the less favorable financial performers in the healthcare sector. In fact, out of 710 companies analyzed within the same sector, Cingulate s ROA ranks lower than most of its peers.

Financial Statements
Cingulate Inc 's Assets	$ 36 million	CING's Balance sheet
Cingulate Inc 's Income	$ -6 million	Quarterly CING's Income Statement
CING's Income by Division		See CING's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-6.98 %	372.56 %	-71 %	-52.92 %	-
Total Assets in million	14	15	3	11	23
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-22	-16	-24	-18	-21
Annual Return On Assets	-163.46 %	-105.28 %	-753.22 %	-164.06 %	-90.49 %

CING's 5 Years Annual ROA >> Back to CING Management Effectiveness >> Compare CING ROA to its Competitors

More Return On Assets Ratios
CING's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CING's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CING's Competitors
Subscribers only: Roa for Cingulate Inc 's Suppliers
Subscribers only: Return On Assets for CING's Customers

You may also want to know
CING's Roi	CING's Inventory Turnover Ratio	CING's Growth Rates	CING's Dividend Comparisons
	CING's Profitability Ratios	CING's Asset Turnover Ratio	CING's Dividend Growth
CING's Roe	CING's Valuation Ratios	CING's Financial Strength Ratios	CING's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:05:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.